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Abstract
Background: Concomitant treatment of Human Immunodeficiency Virus (HIV) infection and tuberculosis (TB)
presents a series of challenges for treatment compliance for both providers and patients. We carried out this study
to identify risk factors for default from TB treatment in people living with HIV.
Methods: We conducted a cohort study to monitor HIV/TB co-infected subjects in Pernambuco, Brazil, on a
monthly basis, until completion or default of treatment for TB. Logistic regression was used to calculate crude and
adjusted odds ratios, 95% confidence intervals and P-values.
Results: From a cohort of 2310 HIV subjects, 390 individuals (16.9%) who had started treatment after a diagnosis of
TB were selected, and data on 273 individuals who completed or defaulted on treatment for TB were analyzed.
The default rate was 21.7% and the following risk factors were identified: male gender, smoking and CD4 T-cell
count less than 200 cells/mm
3. Age over 29 years, complete or incomplete secondary or university education and
the use of highly active antiretroviral therapy (HAART) were identified as protective factors for the outcome.
Conclusion: The results point to the need for more specific actions, aiming to reduce the default from TB
treatment in males, younger adults with low education, smokers and people with CD4 T-cell counts < 200 cells/
mm
3. Default was less likely to occur in patients under HAART, reinforcing the strategy of early initiation of HAART
in individuals with TB.
Background
Tuberculosis (TB) is the leading cause of morbidity and
death among people living with Human Immunodefi-
ciency Virus (HIV), particularly in developing countries
[1]. Brazil is one of 22 countries with a high TB burden
[2] and has about 50 million people infected with Myco-
bacterium tuberculosis [3]. Approximately 14% of
patients with TB are co-infected with HIV [4]. The State
of Pernambuco has the sixth-highest incidence of TB in
the country (44.96 per 100,000 inhabitants) and the sec-
ond highest TB mortality rate (3.7 per 100,000 inhabi-
tants) [5]. In 2008, the percentage of default from TB
treatment in Pernambuco was 11.1%, increasing to
18.3% among subjects co-infected with HIV [6].
Since 1996, Brazil has guaranteed access to antiretro-
viral treatment (ART) to all HIV subjects. Concomitant
treatment of HIV and TB presents a series of challenges,
including a long treatment duration, high frequency of
drug administration, potential complex interactions of
the drugs, toxicity of the two therapies, and the occur-
rence of immune reconstitution syndrome [7,8].
Default from TB treatment is associated with a longer
period of TB transmission, treatment failure and mortal-
ity. Identification of risk factors for default and subse-
quent intervention strategies are required, and are
particularly important in HIV subjects because of the
increase in morbidity and mortality related to progres-
sion of the HIV infection itself. Several studies, using
different approaches and methodologies, [9,10] have
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default from TB treatment in populations that include
or do not include HIV subjects [11-17]. However, few
studies have prospectively examined risk factors for TB
treatment default as the main outcome in a population
of HIV subjects [18]. A prospective study design allows
a proper selection of the variables, appropriate data col-
lection and more accuracy in assessing the risk factors
for treatment default.
This study aimed to estimate the frequency of default
from TB treatment in a cohort co-infected with HIV
and to identify the risk factors for its occurrence.
Methods
Design, location and study population
We conducted a prospective cohort study in HIV sub-
jects older than 18 years who had started treatment
after a diagnosis of TB in two referral hospitals for HIV/
AIDS in the state of Pernambuco, Brazil, from June
2007 to December 2009. These two referral centers are
responsible for the care of about 70% of all HIV subjects
in the State, and they follow the guidelines of the Brazi-
lian Ministry of Health for the treatment of TB and
HIV. In these centers, both treatments are delivered by
t h es a m ep h y s i c i a n .T h es t u d ye x c l u d e dp a t i e n t sw h o s e
TB diagnosis was changed during follow-up (either
because there was no improvement after 2 months of
empirical TB treatment or because they were later
found to have a different diagnosis).
Default from TB treatment was defined as failure of
the patient to attend the clinic for more than 30 conse-
cutive days after the date that the patient was due to
return. Treatment failure was identified by a positive
smear 4 months after the start of treatment. TB treat-
ment outcomes were defined by the Brazilian Ministry
of Health [3]. Successful treatment included cure and
completion of treatment.
Cohort recruitment and follow-up
We enrolled HIV patients in the study at the time they
were notified as having tuberculosis the Surveillance
System for Infectious Diseases (SINAN/MS), managed
by the Brazilian Ministry of Health (MS). Registering
the case in the SINAN/MS is a prerequisite for initiation
of TB treatment.
We included those patients who were likely to have
the opportunity to complete TB treatment before the
end of the investigation, i.e., if they started treatment at
least 6-8 months before the end of the study. We fol-
lowed patients monthly until completion of, or default
from, TB treatment. A trained health professional inter-
viewed all participants, using a standardized question-
naire, after they gave their informed consent. Additional
information was collected from medical records. For
patients who defaulted from TB treatment, information
was extracted from their medical records, from data of
the epidemiological units and from the Mortality Infor-
mation System to avoid misclassification (with death
coded as default).
Definition of terms and study variables
We considered patients to have a diagnosis of active TB
if they had begun TB treatment as a result of clinical
suspicion or laboratory confirmation. We considered
individuals to be HIV-infected if they had been tested
positive for HIV using ELISA, immunofluorescence,
Western blotting or rapid test. For the purposes of the
analysis, independent variables were grouped into five
sections: biological variables; socioeconomic variables;
variables relating to habits and lifestyle; variables relat-
ing to HIV/AIDS and TB-related variables.
In relation to alcohol consumption, we classified
patients as abstainers (never drank or drank less than
eight units a year), light drinkers (drank a maximum of
two days a week, without exceeding ten units per
month), heavy drinkers (drank in excess of five doses a
day at least 3 to 4 days a week), and alcohol dependent
(undergoing treatment for alcoholism).
In relation to smoking, we classified patients as non-
smokers (never smoked in their lives), former smokers
(had stopped smoking at least 6 months prior to study
entry), and smokers (smokers at the time of inclusion in
the study or had stopped smoking less than 6 months
before enrollment).
The criteria used for defining cases of AIDS were
those of the Brazilian Ministry of Health [19].
TB treatment was carried out using the following self-
administered regimens: Regimen I (rifampicin, isoniazid
and pyrazinamide for 2 months, followed by rifampicin
and isoniazid in the last 4 months); Regimen IR (etham-
butol introduced in the first 2 months of Regimen I);
and other regimens (when rifampicin needed to be
replaced by streptomycin and ethambutol because of
drug interactions with antiretroviral therapy (ART))
[20]. HAART was defined as the combination of three
different antiretroviral drugs, regardless of the number
of classes of drugs used. Antiretroviral regimens consist-
ing of two reverse transcriptase inhibitors and efavirenz
are the first choice for patients on HAART and rifampi-
cin [20].
Statistical analysis
The cumulative incidences of TB treatment default, suc-
cessful treatment, and death were calculated. In the ana-
lysis to identify risk factors associated with treatment
default, we excluded patients who died during the study
period or had not completed TB treatment in time to
outcome.
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association of each study variable with default and suc-
cessful TB treatment. The magnitude of the association
was measured by the odds ratio (OR) and its statistical
significance was tested using the OR confidence inter-
val (CI) and the P-value (Chi-square test or maximum
likelihood ratio). The level of significance was set at
P < 0.05.
We carried out the multivariate analysis in two steps:
1) multivariate analysis of each group to determine the
variables closely associated with the outcome: variables
associated with the outcome with P < 0.20 in the uni-
variate analysis were successively included in a multi-
variate logistic regression model, and those showing an
association with a P-value ≤ 0.05 remained in the
model; 2) final multivariate model: the variables selected
in the previous step were introduced in the final multi-
variate model (including variables of all groups) and
those with a P-value ≤ 0.05 were remained in the final
model.
We checked collinearity for those variables which, in
theory, were expected to be associated with each other.
The variables which remained in the final multivariate
model were checked for interaction.
The data entry and double entry validation were per-
formed in parallel with data collection, and the database
was managed by the SQL Server 2000 (Microsoft), using
GeneXus software (version 7.5). STATA version 8.2 for
data analysis.
This study is part of the CSV 182/06 - Clinical-Epide-
miological Study of TB/HIV Co-infection Project in
Recife, approved by the research ethics committee of
The Universidade Federal de Pernambuco (registration
number at SISNEP FR-067 159/CAAE- 0004.1.172.106-
05/REGISTRATION CEP/CCS/UFPE 254/05).
Results
From a cohort of 2310 HIV subjects, 566 patients
(24.5%) who had begun treatment after a diagnosis of
TB were identified. Of these, 170 individuals (30.0%)
were not enrolled in the study because they were not
contactable by the researchers. Six patients were
excluded due to changes in their TB diagnosis (four had
started on empiric treatment based on clinical presenta-
tion but the TB diagnosis was subsequently deemed
erroneous, one was later found to have cryptococcal
meningitis, and one was later diagnosed with histoplas-
mosis). A total of 51 patients (9.0%) started TB treat-
ment during the study period but did not complete
treatment in time to assess their outcome. Of the 339
patients studied, 188 (55.5%) were successfully treated,
85 (25.1%) defaulted from treatment and 66 (19.5%)
died. There was no documented case of treatment fail-
ure, and six patients were lost to follow-up.
A total of 273 patients who were successfully treated
or defaulted from treatment for TB were included in the
analysis, as shown in Figure 1. Comparing the character-
istics of the individuals included in the cohort with
those who began treatment for TB but were not
included in the study (not located by the study staff), we
found that the two populations were similar in age
(mean age ± standard deviation of 36.7 ± 9.6 years for
individuals included in the cohort, versus 37.5 ± 11.3
years for those not included, P = 0.2205), gender (P =
0.39) and TB treatment outcomes (P = 0.991).
The age of the study population ranged from 18 to 67
years, with mean of 36.7 years, and 69.7% were male.
Approximately one-fifth (21.7%) of subjects defaulted
from TB treatment. The univariate analysis of the risk
factors for defaulting from TB treatment is shown in
table 1.
Variables that were significantly associated with treat-
ment default in the multivariate analysis in each group
of variables were included in the final multivariate
model. The variables that remained in the final model
were: sex, age, smoking, education level, CD4 T-cell
count and ART (Table 2). No interactions or collinearity
were found.
Discussion
We observed that 21.7% of HIV subjects receiving TB
treatment defaulted from treatment during our study.
The risk factors identified for TB treatment default in
this cohort were male sex, smoking, and a CD4 count of
less than 200 cells/mm
3.A g eo l d e rt h a n2 9y e a r s ,c o m -
plete or incomplete secondary or university education,
and the use of ART were identified as protective factors
against TB treatment default.
The percentage of TB treatment default found in the
present study was higher than the 14% reported in HIV
subjects in Brazil as a whole [21] but similar to those of
studies in other countriesw i t hah i g hT Bb u r d e n .T h e
high rate of default in our study may reflect the fact
that health services for patients with HIV/AIDS have
neglected to monitor patients who need TB treatment.
Furthermore, Directly Observed Therapy (DOT) is not
operationally feasible in referral hospitals where patients
come from a wide area, such as the whole state of Per-
nambuco which covers approximately 98485 km
2.
It is not clear whether the use of ART has any
impact on defaulting from TB treatment [22,23]. The
complex potential drug interactions between antiretro-
viral drugs and drugs used to treat TB could have a
negative impact on adherence to treatment for both
diseases. However, experts agree that initiation of
HAART should not be delayed, because mortality is
reduced with early initiation of HAART along with
anti-TB treatment [24]. In this study, the use of
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tor against default from TB treatment, as described
[18] in HIV subjects in Thailand. These findings are
relevant because they point to the possibility that the
concomitant use of ART and drugs to treat TB does
not imply a greater likelihood of defaulting from TB
treatment in HIV subjects.
We also found that being male was a risk factor for
TB treatment default. Similar findings have been
reported in populations that included individuals with
and without HIV [25-28]. However, in our study, male
sex was still associated with default from TB treatment
even after adjustment for the effect of smoking and
alcohol consumption. The explanation to our results
Figure 1 Algorithm for the selection of individuals for the study of risk factors for default from tuberculosis (TB) treatment in Human
Immunodeficiency Virus (HIV) infected patients in the State of Pernambuco, 2007-2009.
Maruza et al. BMC Infectious Diseases 2011, 11:351
http://www.biomedcentral.com/1471-2334/11/351
Page 4 of 8Table 1 Univariate analysis of the risk factors for defaulting from TB treatment among HIV subjects in the State of
Pernambuco, 2007-2009
VARIABLES Default Treatment success OR 95% CI P-value
n% n %
BIOLOGICAL
Sex
Female 15 17.6 57 30.3 1.00 - -
Male 70 82.3 131 69.7 2.03 1.07 - 3.84 0.030
Age group
18 to 29 years 33 38.8 35 18.6 1.00 - -
30 to 49 years 48 56.5 131 69.7 0.38 0.21 - 0.69 0.001
50 years or more 4 4.7 22 11.7 0.19 0.06 - 0.61 0.006
Race
White 15 17.6 42 22.3 1.00 - -
Non-white 70 82.3 146 77.7 1.34 0.69 - 2.58 0.378
SOCIOECONOMIC
City of Residence
Recife 39 45.9 78 41.5 1.00 - -
Metropolitan Region 35 41.2 78 41.5 0.89 0.51 - 1.56 0.702
Inland 11 12.9 32 17.0 0.68 0.31 - 1.50 0.350
Marital status
Married 12 14.1 54 28.7 1.00 -
Single/Separated/Widowed 73 85.9 134 71.3 2.45 1.23 - 4.87 0.011
Shared residence
Family/Partner 17 20.0 33 17.6 1.00
Alone 68 80.0 155 82.4 1.74 0.61 - 2.25 0.629
Education level
Complete or incomplete primary education 69 81.2 128 69.1 1.00 - -
Complete or incomplete secondary or university education 16 21.0 60 31.9 0.49 0.26 - 0.92 0.027
Employment
Yes 17 20.0 34 18.1 1.00 - -
No 68 80.0 154 81.9 0.88 0.46 - 1.68 0.707
Income*
< 1 minimum wage 65 22.6 117 37.4 1.00 - -
≥ 1 minimum wage 19 77.4 70 62.6 0.48 0.27 - 0.88 0.017
HABITS
Alcohol consumption
None or light drinker 69 81.2 177 94.1 1.00 - -
Moderate or Heavy drinker 16 18.8 11 5.8 3.73 1.64 - 8.44 0.002
Smoking status
Never smoked 22 25.9 81 43.1 1.00 - -
Former smokers 14 16.5 45 23.9 1.14 0.53 - 2.45 0.727
Current smokers 49 57.6 62 33.0 2.90 1.59 - 5.31 0.001
Illicit drug use
No 63 74.1 129 68.6 1.00
Yes 22 25.9 59 31.4 0.76 0.42 - 1.35 0.358
HIV VARIABLES
Opportunistic Disease
No 13 15.3 32 17.0 1.00 - -
Yes 72 84.7 156 83.0 1.13 0.56 - 2.29 0.722
AIDS
No 3 3.5 6 3.2 1.00 -
Yes 82 96.5 182 97.0 0.90 0.21 - 3.69 0.885
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treatment for TB [29,30] and have a greater need and
desire to be cured and endure adverse drug reactions
during the most critical period [31].
In this study, smoking was identified as an independent
risk factor for TB treatment default. Kittikraisak et al.
[18] have speculated that, among smokers, chronic
respiratory symptoms caused by smoking hinder the
improvement in respiratory symptoms secondary to TB,
which could lead to a lack of belief in the effectiveness of
TB treatment. Another explanation would be that smok-
ing is associated with a lifestyle and risk-related behaviors
that influence compliance with medication regimens [32].
Moreover, smoking may also be related to depression and
poor adherence to treatment, as described by Webb et al.
[33] in HIV subjects taking HAART
Although we found that alcohol consumption was
associated with treatment default in the univariate ana-
lysis, this variable did not remain in the final multivari-
ate model, probably due to the sample size. Illicit drug
use was not significantly associated with TB treatment
default, possibly because of the sample size or because
of questions on illicit drug use are sensitive questions
and may not be answered correctly.
No studies associating a low CD4 T-cell count with
TB treatment default were found in the literature. In
this study, a CD4 T-cell count of less than 200 cells/
mm
3 was associated with a higher frequency of default
from TB treatment. Patients with a lower CD4 count
are more severely ill and therefore it is probably harder
for them to attend clinics and tolerate medications.
However, no association between default from TB treat-
ment and other opportunistic diseases was found.
In this study, we identified that complete or incom-
plete secondary or university education was associated
with a lower risk of defaulting from TB treatment. It is
believed that a low level of education hinders perception
of the seriousness of the disease and causes difficulties
in understanding medical guidelines, leading to a lack of
compliance with use of prescribed medications, as
shown in a study carried out by Natal et al. [16].
One limitation of this study was the fact that not all
individuals who began treatment for TB in the two
health centers participated in the study. However, the
Table 1 Univariate analysis of the risk factors for defaulting from TB treatment among HIV subjects in the State of
Pernambuco, 2007-2009 (Continued)
CD4 T-cell count* (cell/mm
3)
200 or more 33 42.3 114 62.3 1.00 - -
Less than 200 45 57.7 69 37.7 2.25 1.31 - 3.86 0.003
Beginning of HAART
Did not start HAART 33 38.8 23 12.23 1.00 - -
Before treatment for TB 42 49.4 96 51.1 0.30 0.16 - 0.58 0.000
Up to second month of TB treatment 8 9.4 41 21.8 0.13 0.05 - 0.34 0.000
After the second month of TB treatment 2 2.3 28 14.9 0.05 0.01 - 0.23 0.000
TB VARIABLES
Setting of beginning of TB treatment
Outpatient clinic 33 38.8 88 46.8 1.00 - -
Hospital 52 61.2 100 53.2 1.38 0.82 - 2.33 0.220
TB clinical site
Pulmonary 57 32.4 119 67.6 1.00 - -
Extra-pulmonary 19 22.3 47 25.0 0.84 0.45 - 1.56 0.591
Disseminated 9 10.6 22 11.7 0.85 0.63 - 1.97 0.369
Type of regimen for TB treatment
Regimen 1 62 75.9 134 71.3 1.00 - -
Regimen 1R 19 22.3 41 21.8 1.00 0.53 - 1.86 0.996
Other regimens 4 4.7 13 6.9 0.66 0.20 - 2.12 0.491
Adverse effects
No 76 89.4 171 91.0 1.00 - -
Yes 9 10.6 17 9.0 1.19 0.50 - 2.79 0.687
Previous Treatment
No 39 45.9 84 44.7 1.00 - -
Yes 46 30.7 104 69.3 0.95 0.56 - 1.59 0.853
OR, odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy.
*The number of individuals varied because of missing values.
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Page 6 of 8inclusion or exclusion of potentially eligible was mainly
to the difficulties experienced in recruiting patients. It is
believed that this did not interfere with the association
found, since a comparison of individuals included and
not included in the study showed no differences regard-
ing sex, age, and percentage of success and default from
treatment for TB. Another limitation is that, as HIV
patients are usually paucibacillary and there were cases
of extra-pulmonary TB in the study population, only a
few cases had a positive smear and culture at the time
of the diagnosis of TB. Therefore, there was no docu-
mented case of treatment failure.
Conclusions
In the present study, we observed a high rate of default
from TB treatment, even though both treatments, for
HIV infection and TB, were being conducted in the
same department responsible for monitoring the patient,
a scenario which should have contributed to reducing
the default rate in the study population.
The results indicate that there is still need for action
to be taken to reduce rates of default from TB treatment
in specific groups, in particular males, younger indivi-
duals and those with a low level of education. Moderate
and heavy drinkers are also a group to be targeted.
The associations of smoking and CD4 T-cell count
less than 200 cells/mm
3 with TB treatment default need
to be better understood for more appropriate interven-
tion planning to reduce treatment default in these
subjects.
An important finding of this study is that the use of
HAART was protective against TB treatment default.
This reinforces the strategy of early initiation of
HAART in HIV individuals with TB.
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Table 2 Final model of the risk factors for defaulting from TB treatment among HIV subjects in the State of
Pernambuco, 2007-2009
Variables ORadj 95% CI P-value
Sex
Female 1.00
Male 2.28 1.06 - 4.94 0.036
Age group
18 to 29 years 1.00
30 years or more 0.50 0.25 - 0.99 0.047
Education level
Complete or incomplete primary education 1.00
Complete or incomplete secondary or university education 0.33 0.15 - 0.71 0.005
Smoking status
Never smoked 1.00
Former smoker 1.07 0.43 - 2.67 0.876
Current smoker 2.62 1.31 - 5.26 0.007
CD4 T-cell count
200 or more 1.00
Less than 200 2.93 1.56 - 5.23 0.001
HAART use
Did not start HAART 1.00
Before treatment for TB 0.32 0.15 - 0.67 0.003
At any time during TB treatment 0.12 0.05 - 0.33 0.000
ORadj, adjusted OR.
Alcohol consumption was included in the final multivariate model but it was subsequently excluded because it was not statistically significant.
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